Overview

Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis

Status:
Unknown status
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a limited duration of treatment (two weeks of low molecular weight treatment) is a safe and effective treatment for distal deep vein thrombosis of the lower limb.
Phase:
Phase 4
Details
Lead Sponsor:
Monash Medical Centre
Collaborators:
Auckland City Hospital
Christchurch Hospital, NZ
Eastern Health, Victoria
Middlemore Hospital, New Zealand
North Shore Hospital, New Zealand
Prince of Wales Hospital, Sydney
Royal Adelaide Hospital, Adelaide
Southern Health, Victoria
Treatments:
Dalteparin
Enoxaparin
Heparin
Heparin, Low-Molecular-Weight